

Seeking Drug Discovery Projects Targeting Itch in Inflammatory Conditions

Grünenthal, a global leader in pain management and related diseases, is seeking **therapeutic molecules for oral administration** that address both the **inflammatory and itch components of inflammatory diseases**, such as atopic dermatitis. The team is particularly interested in innovative approaches that address the **neuroimmune drivers of chronic itch**, via **targeting itch-mediating pruriceptors** or approaches that **modulate the immune-pruriceptor interaction**.



Approaches of Interest:

- Diseases of particular interest include dermatological diseases, including but not limited to **atopic dermatitis, hidradenitis suppurativa, urticaria and prurigo nodularis**
- Therapeutic molecules developed for **non-dermatological inflammatory diseases** targeting **relevant pathways** for the treatment of itch
- **Focus on small molecule** assets for **oral/ systemic administration**

Out of Scope:

- Therapeutics for **topical administration**
- Drug discovery platforms
- Clinical stage opportunities

Developmental Stages of Interest:

- Opportunities that have **tangible chemical matter** to **late preclinical** are in scope
- Opportunities at **lead optimization** stage are highest priority




Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should contain information on the **therapeutics molecule's mode of action or scientific rationale**, any **completed experimental validation**, and how it is **differentiated from known approaches**. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Grünenthal is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

-  Technologies
-  Centres of excellence
-  Research projects
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **8th June 2026 - 10:59 pm GMT**

Have any questions?

Contact our team at campaigns@inpart.io



Grünenthal is a science-based, fully integrated pharmaceutical company leading in pain management. They have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.